Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21939669 | 0.86 | ADORA3 (0.71) | ADORA3 | |
| SCHEMBL22359582 | 0.86 | ADORA3 (0.58) | ADORA3 | |
| SCHEMBL30255514 | 0.85 | ADORA3 (0.76) | ADORA3 | |
| SCHEMBL20122175 | 0.85 | ADORA3 (0.76) | ADORA3 | |
| SCHEMBL16774173 | 0.85 | ADORA3 (0.76) | ADORA3 | |
| SCHEMBL23097520 | 0.85 | ADORA3 (0.75) | ADORA3 | |
| SCHEMBL22359601 | 0.85 | ADORA3 (0.75) | ADORA3 | |
| SCHEMBL20122123 | 0.84 | ADORA3 (0.75) | ADORA3 | |
| SCHEMBL23097648 | 0.82 | ADORA3 (0.59) | ADORA3 | |
| SCHEMBL23097630 | 0.82 | ADORA3 (0.75) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117985-A1 | TREATMENT OF CHRONIC HEADACHES | UNIVERSITY OF MARYLAND, BALTIMORE | 2022-04-21 | — | — | US | disclosed |
| EP-3074398-B1 | A3 ADENOSINE RECEPTOR AGONISTS | US HEALTH (US) | 2021-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117985-A1 | TREATMENT OF CHRONIC HEADACHES | ADORA3, ADORA2B, ADORA2A | ADORA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.